President Expected to Address Drug Prices in State of the Union Message

President Expected to Address Drug Prices in State of the Union Message

In his State of the Union address tonight, President Trump is expected to announce an initiative to make insulin more affordable and to challenge Congress to pass legislation

Read More »

CMS Unveils Medicaid Block Grant Option, Ramifications for 340B Unclear

CMS Unveils Medicaid Block Grant Option, Ramifications for 340B Unclear

The Centers for Medicare & Medicaid Services (CMS) this morning invited state Medicaid directors to pilot test giving up open-ended federal Medicaid funding for able-bodied adults in exchange for a

Read More »

Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law”

Hospital Group: GAO’s 340B Duplicate Discount Recommendations “Contrary to Federal Law”

Hospital group 340B Health yesterday swung back hard against a congressional watchdog agency’s recommendations for stricter federal policing of 340B duplicate discounts, calling them “misguided, unworkable, and contrary

Read More »

Breaking News

BREAKING: GAO Criticizes Policing of 340B Duplicate Discounts

BREAKING: GAO Criticizes Policing of 340B Duplicate Discounts

The U.S. Department of Health and Human Services (HHS) lacks “reasonable assurance” that states and healthcare providers are complying with the prohibition against subjecting drug manufacturers to payment of duplicate 340B discounts

Read More »

Vermont Bills Would Require 340B Hospitals to Report Drug Discount Savings and Spending

Vermont Bills Would Require 340B Hospitals to Report Drug Discount Savings and Spending

Companion bills filed this month in the Vermont House and Senate would require hospitals to report how much money they save through the 340B program

Read More »

Massachusetts Medicaid Wants to Stop Covering “High Cost” Drugs Bought Through 340B

(Editor’s note: The Medicare Payment Advisory Commission (MedPAC) tomorrow will consider a staff analysis of “whether the availability of 340B drug discounts creates incentives to choose more expensive products in some cases and the resulting impact on Medicare patients’ cost-share

Read More »

Breaking News

BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility

BREAKING: GAO Says HRSA Should Strengthen Oversight Over Private-Nonprofit Hospitals’ 340B Eligibility

The Health Resources and Services Administration’s (HRSA) oversight of 340B private, nonprofit hospitals should be significantly strengthened, the Government Accountability Office (GAO) found in a report released

Read More »

Breaking News

BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says

BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says

The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts

Read More »

Breaking News

BREAKING: Drugmaker Xspire Owes 340B Refunds

Greetings

Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.

BREAKING: Drugmaker Xspire Owes 340B Refunds

Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live